Sarepta Therapeutics Stock Forum

Analysts see the shortened timeline and absence of an advisory committee meeting as positive signs for unrestricted approval. The FDA's eagerness to expand the label and transition from accelerated to traditional approval is evident in the expedited review timeline. This could set a precedent for other gene therapies seeking FDA approval, despite Elevidys not meeting its primary endpoint.

Sarepta Therapeutics' low P/S ratio reflects its poor revenue outlook. The market anticipates limited growth, hence the reduced stock price. Even a recent share price surge couldn't bring the P/S to industry median. A strong share price rise seems unlikely under these conditions.

The promise for a bright 2024 comes after two years of abysmal performance of biopharma stocks. The S&P Biotechnology Select Industry Index surged 43% from its recent low in October 2023, reaching a new high since April 2022.
Source: S&P
A stable-to-improving environment characterized by falling inflation, low unemployment and the easing of hospital staffing pressures position medte...

Analysts are bullish on Sarepta's future, predicting full U.S. approval. Strong demand for the therapy among eligible patients is also anticipated. The FDA is unlikely to withdraw the drug's accelerated approval and may expand Elevidys's label.

Investors are likely expecting limited future growth for Sarepta Therapeutics, reflected in the company's low P/S ratio. A continued weak growth forecast might hinder any sharp increase in its share price.